Quantification of CYFRA21-1 antigen in non-small cell lung cancer by Phage Display Real-time Immuno-PCR Method

Abstract

Lung cancer is one of the most severe and frequent types of cancer in men, from 50 to 70 years of age. There are two main types: small cell lung cancer and non-small cell lung cancer. Non-small cell lung cancer (NSCLC) accounts for about 80%. CYFRA21-1 antigen is associated explicitly with NSCLC according to recent studies on lung cancer and the mechanism of lung cancer generation. In the serum of healthy people, CYFRA21-1 antigen content makes up ≤ 3.3 ng/mL. However, for those who appear NSCLC, this content increases very quickly. The concentration of CYFRA21-1 antigen in serum is directly proportional to the stage of cancer development. The higher the concentration, the shorter the lifetime of the patient. Therefore, it is possible to study the increase in serum CYFRA21-1 levels as a sign of early identification of NSCLC. The Phage Display Real-time Immuno-PCR method (PDRTI-PCR) was used in this study to quantify CYFRA21-1 antigen in NSCLC patients. PDRTI-PCR method has a combination of specificity of ELISA with sensitivity of Real-time PCR technique and phage display technique. Quantification of CYFRA21-1 antigen by PDRTI-PCR method provides reliable sensitivity and accuracy, which is the basis for creating an NSCLC early diagnosis kit.